In vitro human immunodeficiency virus eradication by autologous CD8+ T cells expanded with inactivated-virus-pulsed dendritic cells

Journal of Virology

Volumn 75, Issue 19, 2001, Pages 8949-8956

  Lu, W ^a   Andrieu, J M ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD8 ANTIGEN; INDINAVIR; THIOL DERIVATIVE;

ADULT; ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; ARTICLE; CELL KILLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; ERADICATION THERAPY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS IMMUNITY; VIRUS INACTIVATION;

ANTI-HIV AGENTS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; MALE;

EID: 0034858032     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.19.8949-8956.2001     Document Type: Article

References (30)

1. T-cell apoptosis in HIV-1-infected individuals receiving highly active antiretroviral therapy
2. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection
3. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
4. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
5. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
6. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
7. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
8. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
9. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART)
10. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
11. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression
12. Toward an understanding of the correlates of protective immunity to HIV infection
13. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients
14. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
15. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study
16. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
17. Improvement in CD4+ cell counts despite persistently detectable HIV load
18. T-cell recovery in HIV-infected patients experiencing virologic failure under highly active antiretroviral therapy
19. HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: A viral-suppression-independent mechanism
20. Prospective views of HIV pathology. Clues for therapeutic strategies
21. Equivalent amplification of intrinsically variable nucleic acid sequences by multiple-primer-induced overlapping amplification assay: Applications for universal detection and quantitation
22. Multi-target PCR analysis by capillary electrophoresis and laser-induced fluorescence
23. Escape of human immunodeficiency virus from immune control
24. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins
25. Lysis of CD4+ T cells expressing HIV-1 gag peptides by gag-specific CD8+ cytotoxic T cells
26. + T-cell decrease
27. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice
28. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo
29. HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines
30. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells